Clinical trial
Octreotide Efficacy and Safety in First-line Acromegalic Patients
NCT00171886 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Octreotide Efficacy and Safety in First-line Acromegalic Patients
- Lead sponsor
- Novartis Pharmaceuticals
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- July 31, 2002
- Completion date
- May 31, 2006
- Enrollment
- 20 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.